1. Pediatric M5 acute myeloid leukemia with MLL-SEPT6 fusion and a favorable outcome
- Author
-
Claudia Djambas Khayat, Tony Yammine, Warde Semaan, Rima Korban, Alain Chebly, Jessica Bou Zeid, and Chantal Farra
- Subjects
Oncology ,MLL ,medicine.medical_specialty ,Anemia ,medicine.medical_treatment ,Article ,FAVORABLE RESPONSE ,AML ,Internal medicine ,hemic and lymphatic diseases ,medicine ,SEPT6 ,Septin ,Leukocytosis ,Favorable outcome ,neoplasms ,RC254-282 ,Chemotherapy ,Acute myeloid leukemia ,business.industry ,Genetic variants ,Myeloid leukemia ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Hematology ,medicine.disease ,medicine.symptom ,Abnormality ,business - Abstract
Acute myeloid leukemia (AML) patients with MLL-SEPT6 fusion represent a small subset of AML. The uncommon MLL-SEPT6 rearrangement results from t(X;11) or other variants like ins(X;11), and it is usually associated with complex cytogenetic abnormalities. We herein report a case of AML-M5-infant with ins(X;11)(q24;q23q13) and MLL-SEPT6. The one-year-old boy presented with leukocytosis, anemia and thrombocytopenia. He had a favorable response to chemotherapy according to ELAM02protocol and is currently in complete remission. We here, highlight the occurrence of MLL-SEPT6 as the sole abnormality in a pediatric-AML-M5 case, discuss the prognostic implication of this genetic variant, while reviewing previously reported AML-MLL-SEPT6 cases.
- Published
- 2021